PTX.ASX: Groundbreaking Phase 2 Progress | Unlocking Cancer Therapies
In this exclusive interview, Jess Fertig hosts James McDonnell, CEO of Prescient Therapeutics (ASX: PTX),...
In this exclusive interview, Jess Fertig hosts James McDonnell, CEO of Prescient Therapeutics (ASX: PTX),...
What is Relapsed or Refractory T-Cell Lymphoma? Why is it so difficult to treat? What...
In this HotCopper Capital Compass interview, Prescient Therapeutics (ASX:PTX) CEO James McDonnell discusses the company’s progress with PTX-100, a...
Prescient Therapeutics: Shareholder Briefing with CEO James McDonnell CEO James McDonnell, held a shareholder briefing...
Prescient Therapeutics: Q&A Update with Dr James Campbell Reach Markets recently interviewed Dr James Campbell...
Prescient Therapeutics: Investor Briefing with CEO James McDonnell CEO and Managing Director, James McDonnell, held...
With new CEO James McDonnell in place and FDA clearance for its Investigational New Drug application, 2025...
Proactive’s Tylah Tully gives a wrap of some of the strongest performers this week in...
Prescient Therapeutics Ltd has resolved the technical difficulties facing its OmniCAR program by creating a...
Proactive’s Tylah Tully breaks down ‘Just the Facts’ of the latest news from Prescient Therapeutics...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.